English 
PHC 株式会社は、CCRM 社と、細胞・遺伝子治療（CGT）製品の製造加速を目指したプライマリー T 細胞増殖培養プロセスの開発に関する共同研究契約を締結しました。この共同イニシアチブは、PHCが開発中の細胞増殖システム「LiCellGrow」とCCRMの再生医療およびバイオマニュファクチャリングに関する深い知識を統合し、CGTの細胞培養効率と品質を向上させる新たな培養プロセスを確立するものです。
プライマリーT細胞は、CAR-T細胞療法などのCGTのプロセス開発や製造に使用されます。しかし、患者から直接得られたプライマリーT細胞は、増殖速度や品質に大きなばらつきがあることが多く、研究者が培養プロセスを通じて安定した細胞数を確保し、品質を維持することは困難です。このような課題に対処し、細胞ベースの治療薬の質を向上させるためには、より優れた細胞培養プロセスが必要です。
Chikara Takauo, Director of PHC and Head of the Biomedical Division that leads the company’s Life Science business, commented: “We are delighted to begin this joint research and development initiative with CCRM, a leader with 14 years of experience in the commercialization of regenerative medicine and CGT. By combining the technologies and expertise of both of our organizations, we aim to advance the manufacturing processes for cell-based therapeutics and cell culture technologies, contributing to the early practical application of CGT.”
こちらもお読みください： プリモ、アジア太平洋地域でプレシジョン・オンコロジーを推進するためシャインと提携
PHC has developed proprietary In-Line monitoring technology to track key indicators of cell metabolism in real-time, which can help researchers address issues like cell quality and reproducibility, and establish optimal cell culture methods. This technology enables precise, continuous measurement of glucose uptake and lactate production during cell culture, providing a more precise understanding of changes in cell metabolism over time than is possible to observe using traditional sampling methods. In 2024, PHC launched the live-cell metabolic analyzer “LiCellMo” incorporating this technology in the United States, Canada, Europe and some Asian markets including Japan, China, Singapore and Taiwan.
Building on this technology, the company is also developing “LiCellGrow,” a cell expansion system designed to exchange media automatically based on the metabolic state of the cells and to maintain the culture environment in an optimal state. PHC aims to further expand its product lineup to seamlessly support research, process development, and commercial manufacturing of cell-based therapeutics.
“We are excited to collaborate with PHC to unlock new possibilities in cell culture,” explained Michael May, President and CEO of CCRM. “Technology development partnerships, like this one, are key to advancing the industry and making CGT more cost effective, and therefore more accessible to patients around the world.”
との共同研究 シーシーアールエム を許可します。 ピーエイチシー to analyze culture conditions using “LiCellGrow” to establish optimal culture processes for primary T-cells. The collaboration will seek to accelerate LiCellGrow’s development, contributing to improved cell quality, enhanced manufacturing efficiency, and cost reduction in the production of cell-based therapeutics.
ソース ビジネスワイヤー
日本語